SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that Dalian Orientech Co. Ltd (“Orientech”), the Company’s exclusive China distributor, has purchased a BSD-2000 Hyperthermia System (BSD-2000). The Company recently announced the renewal of the distributorship agreement with Orientech and this is the first of several BSD-2000 orders per year required under the 4-year contract with Orientech. Orientech has placed a significant number of BSD-2000 Hyperthermia Systems in leading hospitals in China, including a recent installation at Jiamusi Tumour Hospital, a premier oncology hospital in China. The BSD-2000 System utilizes BSD’s proprietary synchronous phased array technology to non-invasively target therapeutic heating (hyperthermia) to certain cancerous tumors, including those located deep within the body. Studies have shown that hyperthermia treatment can kill cancer cells directly as well as increase the effectiveness of other cancer therapies, including radiation therapy, for the treatment of certain tumors.
Hyperthermia cancer therapy has a strong following in China, and Orientech is recognized as the leading hyperthermia company in China. The Orientech sales force covers 23 provinces. The hyperthermia market in China has historically been supported by Chinese manufactured systems. The market objective for BSD in China is to continue to expand and upgrade the existing market for clinical hyperthermia equipment to the advanced features of the BSD-2000.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
BSD Medical Corporation
Dennis Gauger, 801-972-5555
KEYWORDS: United States Asia Pacific North America China Utah
INDUSTRY KEYWORDS: Health Hospitals Medical Devices Oncology Radiology General Health